MedTrace Logo

A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration

NCT03021785 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-03-01

No results posted yet for this study

Summary

This is a multicenter, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of multiple intravitreal injection TK001 in patients with AMD. It consists of core study (12 weeks) and extension study (40 weeks).

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

BIOLOGICAL

TK001

TK001 will be administered intravitreal injection.

Sponsors & Collaborators

  • Jiangsu T-Mab Biopharma Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Ming Zhang · West China Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-18
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03021785 on ClinicalTrials.gov